文献速递消化道肿瘤放疗

MR引导自适应同步整合加量放疗至原发灶及阳性淋巴结在局部晚期直肠癌新辅助治疗中的疗效与安全性:一项随机对照III期试验

Efficacy and safety of MR-guided adaptive simultaneous integrated boost radiotherapy to primary lesions and positive lymph nodes in the neoadjuvant treatment of locally advanced rectal cancer: a randomized controlled phase III trial.
PubMed 文献 · Radiat Oncol · 2024-09-12

本研究为多中心随机对照III期试验(NCT06246344),计划纳入128例cT3-4/N+局部晚期直肠癌患者,比较MR引导自适应放疗同步整合加量至原发灶及阳性淋巴结(60-65 Gy/25-28次,盆腔50-50.4 Gy/25-28次)与调强放疗(50-50.4 Gy/25-28次)在新辅助治疗中的疗效与安全性,两组均同步卡培他滨化疗并巩固化疗。主要终点为病理完全缓解率和手术难度。

要点

  • 试验针对LARC原发灶及阳性淋巴结同步整合加量,基于MRgART实现精准照射。
  • 试验组原发灶及阳性淋巴结60-65 Gy/25-28次,盆腔50-50.4 Gy/25-28次。
  • 主要终点为pCR率和手术难度,计划纳入128例cT3-4/N+患者。

核心结论

  • 作者提出开展III期试验以评估基于MRgART对LARC原发灶及阳性淋巴结行SIB的疗效与安全性。

研究设计与样本

  • 多中心、随机、对照III期试验(NCT06246344),计划纳入128例cT3-4/N+局部晚期直肠癌患者。
  • 试验组接受MRgART同步整合加量:原发灶及阳性淋巴结60-65 Gy/25-28次,盆腔50-50.4 Gy/25-28次。
  • 对照组接受调强放疗50-50.4 Gy/25-28次。
  • 两组均同步卡培他滨化疗,放疗与手术间行巩固化疗:2周期CAPEOX或3周期FOLFOX。

关键数值与推荐

  • 主要终点为病理完全缓解(pCR)率和手术难度。
  • 次要终点包括临床完全缓解(cCR)率、3年和5年无病生存(DFS)率及总生存(OS)率、急性和晚期毒性及生活质量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In locally advanced rectal cancer (LARC), optimizing neoadjuvant strategies, including the addition of concurrent chemotherapy and dose escalation of radiotherapy, is essential to improve tumor regression and subsequent implementation of anal preservation strategies. Currently, dose escalation studies in rectal cancer have focused on the primary lesions. However, a common source of recurrence in LARC is the metastasis of cancer cells to the proximal lymph nodes. In our trial, we implement simultaneous integrated boost (SIB) to both primary lesions and positive lymph nodes in the experimental group based on magnetic resonance-guided adaptive radiotherapy (MRgART), which allows for more precise (and consequently intense) targeting while sparing neighboring healthy tissue. The objective of this study is to evaluate the efficacy and safety of MRgART dose escalation to both primary lesions and positive lymph nodes, in comparison with the conventional radiotherapy of long-course concurrent chemoradiotherapy (LCCRT) group, in the neoadjuvant treatment of LARC. METHODS: This is a multi-center, randomized, controlled phase III trial (NCT06246344). 128 patients with LARC (cT3-4/N+) will be enrolled. During LCCRT, patients will be randomized to receive either MRgART with SIB (60-65 Gy in 25-28 fractions to primary lesions and positive lymph nodes; 50-50.4 Gy in 25-28 fractions to the pelvis) or intensity-modulated radiotherapy (50-50.4 Gy in 25-28 fractions). Both groups will receive concurrent chemotherapy with capecitabine and consolidation chemotherapy of either two cycles of CAPEOX or three cycles of FOLFOX between radiotherapy and surgery. The primary endpoints are pathological complete response (pCR) rate and surgical difficulty, while the secondary endpoints are clinical complete response (cCR) rate, 3-year and 5-year disease-free survival (DFS) and overall survival (OS) rates, acute and late toxicity and quality of life. DISCUSSION: Since dose escalation of both primary lesions and positive nodes in LARC is rare, we propose conducting a phase III trial to evaluate the efficacy and safety of SIB for both primary lesions and positive nodes in LARC based on MRgART. TRIAL REGISTRATION: The study was registered at ClinicalTrials.gov with the Identifier: NCT06246344 (Registered 7th Feb 2024).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wang H, Zhang X, Leng B, et al. Efficacy and safety of MR-guided adaptive simultaneous integrated boost radiotherapy to primary lesions and positive lymph nodes in the neoadjuvant treatment of locally advanced rectal cancer: a randomized controlled phase III trial. Radiat Oncol. 2024. PMID: 39267085. doi:10.1186/s13014-024-02506-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。